

Global Adrenoleukodystrophy Treatment Market Growth (Status and Outlook) 2023-2029

<https://marketpublishers.com/r/G58896F17D8BEN.html>

Date: February 2023

Pages: 121

Price: US\$ 3,660.00 (Single User License)

ID: G58896F17D8BEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Adrenoleukodystrophy refers to a rare genetic condition that causes the buildup of long chain fatty acids (VLCFAs) in the brain. ALD is led by a mutation in the ABCD1 gene on the X chromosome. The three types of adrenoleukodystrophy including Adrenomyelopathy, Childhood cerebral ALD and Addison's disease. Childhood cerebral ALD is known to progress rapidly in children between the ages of 3 and 10.

LPI (LP Information)' newest research report, the "Adrenoleukodystrophy Treatment Industry Forecast" looks at past sales and reviews total world Adrenoleukodystrophy Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Adrenoleukodystrophy Treatment sales for 2023 through 2029. With Adrenoleukodystrophy Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Adrenoleukodystrophy Treatment industry.

This Insight Report provides a comprehensive analysis of the global Adrenoleukodystrophy Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Adrenoleukodystrophy Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Adrenoleukodystrophy Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors

shaping the global outlook for Adrenoleukodystrophy Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Adrenoleukodystrophy Treatment.

The global Adrenoleukodystrophy Treatment market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Adrenoleukodystrophy Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Adrenoleukodystrophy Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Adrenoleukodystrophy Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Adrenoleukodystrophy Treatment players cover bluebird bio, Orpheris, MedDay Pharmaceuticals, MINORYX THERAPEUTICS SL, Pfizer, Amgen, AstraZeneca, Abbott and agtc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Adrenoleukodystrophy Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Oral Drugs

Parenteral Drugs

Segmentation by application

Hospital

Clinic

Home Care

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

bluebird bio

Orpheris

MedDay Pharmaceuticals

MINORYX THERAPEUTICS SL

Pfizer

Amgen

AstraZeneca

Abbott

agtc

ReceptoPharm

The Myelin Project

SOM Biotech

Viking Therapeutics

Nutra Pharma Corporation

Genetix Biotech

Magenta Therapeutics

NeuroVia

Novartis

CELGENE CORPORATION

Jazz Pharmaceuticals

Sanofi

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Adrenoleukodystrophy Treatment Market Size 2018-2029
 - 2.1.2 Adrenoleukodystrophy Treatment Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 Adrenoleukodystrophy Treatment Segment by Type
 - 2.2.1 Oral Drugs
 - 2.2.2 Parenteral Drugs
- 2.3 Adrenoleukodystrophy Treatment Market Size by Type
 - 2.3.1 Adrenoleukodystrophy Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029)
 - 2.3.2 Global Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)
- 2.4 Adrenoleukodystrophy Treatment Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Clinic
 - 2.4.3 Home Care
- 2.5 Adrenoleukodystrophy Treatment Market Size by Application
 - 2.5.1 Adrenoleukodystrophy Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029)
 - 2.5.2 Global Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)

3 ADRENOLEUKODYSTROPHY TREATMENT MARKET SIZE BY PLAYER

- 3.1 Adrenoleukodystrophy Treatment Market Size Market Share by Players
 - 3.1.1 Global Adrenoleukodystrophy Treatment Revenue by Players (2018-2023)
 - 3.1.2 Global Adrenoleukodystrophy Treatment Revenue Market Share by Players (2018-2023)
- 3.2 Global Adrenoleukodystrophy Treatment Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
 - 3.3.1 Competition Landscape Analysis
 - 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion

4 ADRENOLEUKODYSTROPHY TREATMENT BY REGIONS

- 4.1 Adrenoleukodystrophy Treatment Market Size by Regions (2018-2023)
- 4.2 Americas Adrenoleukodystrophy Treatment Market Size Growth (2018-2023)
- 4.3 APAC Adrenoleukodystrophy Treatment Market Size Growth (2018-2023)
- 4.4 Europe Adrenoleukodystrophy Treatment Market Size Growth (2018-2023)
- 4.5 Middle East & Africa Adrenoleukodystrophy Treatment Market Size Growth (2018-2023)

5 AMERICAS

- 5.1 Americas Adrenoleukodystrophy Treatment Market Size by Country (2018-2023)
- 5.2 Americas Adrenoleukodystrophy Treatment Market Size by Type (2018-2023)
- 5.3 Americas Adrenoleukodystrophy Treatment Market Size by Application (2018-2023)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Adrenoleukodystrophy Treatment Market Size by Region (2018-2023)
- 6.2 APAC Adrenoleukodystrophy Treatment Market Size by Type (2018-2023)
- 6.3 APAC Adrenoleukodystrophy Treatment Market Size by Application (2018-2023)
- 6.4 China
- 6.5 Japan
- 6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Adrenoleukodystrophy Treatment by Country (2018-2023)

7.2 Europe Adrenoleukodystrophy Treatment Market Size by Type (2018-2023)

7.3 Europe Adrenoleukodystrophy Treatment Market Size by Application (2018-2023)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Adrenoleukodystrophy Treatment by Region (2018-2023)

8.2 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Type (2018-2023)

8.3 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Application (2018-2023)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL ADRENOLEUKODYSTROPHY TREATMENT MARKET FORECAST

10.1 Global Adrenoleukodystrophy Treatment Forecast by Regions (2024-2029)

10.1.1 Global Adrenoleukodystrophy Treatment Forecast by Regions (2024-2029)

10.1.2 Americas Adrenoleukodystrophy Treatment Forecast

- 10.1.3 APAC Adrenoleukodystrophy Treatment Forecast
- 10.1.4 Europe Adrenoleukodystrophy Treatment Forecast
- 10.1.5 Middle East & Africa Adrenoleukodystrophy Treatment Forecast
- 10.2 Americas Adrenoleukodystrophy Treatment Forecast by Country (2024-2029)
 - 10.2.1 United States Adrenoleukodystrophy Treatment Market Forecast
 - 10.2.2 Canada Adrenoleukodystrophy Treatment Market Forecast
 - 10.2.3 Mexico Adrenoleukodystrophy Treatment Market Forecast
 - 10.2.4 Brazil Adrenoleukodystrophy Treatment Market Forecast
- 10.3 APAC Adrenoleukodystrophy Treatment Forecast by Region (2024-2029)
 - 10.3.1 China Adrenoleukodystrophy Treatment Market Forecast
 - 10.3.2 Japan Adrenoleukodystrophy Treatment Market Forecast
 - 10.3.3 Korea Adrenoleukodystrophy Treatment Market Forecast
 - 10.3.4 Southeast Asia Adrenoleukodystrophy Treatment Market Forecast
 - 10.3.5 India Adrenoleukodystrophy Treatment Market Forecast
 - 10.3.6 Australia Adrenoleukodystrophy Treatment Market Forecast
- 10.4 Europe Adrenoleukodystrophy Treatment Forecast by Country (2024-2029)
 - 10.4.1 Germany Adrenoleukodystrophy Treatment Market Forecast
 - 10.4.2 France Adrenoleukodystrophy Treatment Market Forecast
 - 10.4.3 UK Adrenoleukodystrophy Treatment Market Forecast
 - 10.4.4 Italy Adrenoleukodystrophy Treatment Market Forecast
 - 10.4.5 Russia Adrenoleukodystrophy Treatment Market Forecast
- 10.5 Middle East & Africa Adrenoleukodystrophy Treatment Forecast by Region (2024-2029)
 - 10.5.1 Egypt Adrenoleukodystrophy Treatment Market Forecast
 - 10.5.2 South Africa Adrenoleukodystrophy Treatment Market Forecast
 - 10.5.3 Israel Adrenoleukodystrophy Treatment Market Forecast
 - 10.5.4 Turkey Adrenoleukodystrophy Treatment Market Forecast
 - 10.5.5 GCC Countries Adrenoleukodystrophy Treatment Market Forecast
- 10.6 Global Adrenoleukodystrophy Treatment Forecast by Type (2024-2029)
- 10.7 Global Adrenoleukodystrophy Treatment Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

- 11.1 bluebird bio
 - 11.1.1 bluebird bio Company Information
 - 11.1.2 bluebird bio Adrenoleukodystrophy Treatment Product Offered
 - 11.1.3 bluebird bio Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.1.4 bluebird bio Main Business Overview

- 11.1.5 bluebird bio Latest Developments
- 11.2 Orpheris
 - 11.2.1 Orpheris Company Information
 - 11.2.2 Orpheris Adrenoleukodystrophy Treatment Product Offered
 - 11.2.3 Orpheris Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.2.4 Orpheris Main Business Overview
 - 11.2.5 Orpheris Latest Developments
- 11.3 MedDay Pharmaceuticals
 - 11.3.1 MedDay Pharmaceuticals Company Information
 - 11.3.2 MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Product Offered
 - 11.3.3 MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.3.4 MedDay Pharmaceuticals Main Business Overview
 - 11.3.5 MedDay Pharmaceuticals Latest Developments
- 11.4 MINORYX THERAPEUTICS SL
 - 11.4.1 MINORYX THERAPEUTICS SL Company Information
 - 11.4.2 MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Product Offered
 - 11.4.3 MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.4.4 MINORYX THERAPEUTICS SL Main Business Overview
 - 11.4.5 MINORYX THERAPEUTICS SL Latest Developments
- 11.5 Pfizer
 - 11.5.1 Pfizer Company Information
 - 11.5.2 Pfizer Adrenoleukodystrophy Treatment Product Offered
 - 11.5.3 Pfizer Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.5.4 Pfizer Main Business Overview
 - 11.5.5 Pfizer Latest Developments
- 11.6 Amgen
 - 11.6.1 Amgen Company Information
 - 11.6.2 Amgen Adrenoleukodystrophy Treatment Product Offered
 - 11.6.3 Amgen Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.6.4 Amgen Main Business Overview
 - 11.6.5 Amgen Latest Developments
- 11.7 AstraZeneca
 - 11.7.1 AstraZeneca Company Information

- 11.7.2 AstraZeneca Adrenoleukodystrophy Treatment Product Offered
- 11.7.3 AstraZeneca Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
- 11.7.4 AstraZeneca Main Business Overview
- 11.7.5 AstraZeneca Latest Developments
- 11.8 Abbott
 - 11.8.1 Abbott Company Information
 - 11.8.2 Abbott Adrenoleukodystrophy Treatment Product Offered
 - 11.8.3 Abbott Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.8.4 Abbott Main Business Overview
 - 11.8.5 Abbott Latest Developments
- 11.9 agtc
 - 11.9.1 agtc Company Information
 - 11.9.2 agtc Adrenoleukodystrophy Treatment Product Offered
 - 11.9.3 agtc Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.9.4 agtc Main Business Overview
 - 11.9.5 agtc Latest Developments
- 11.10 ReceptoPharm
 - 11.10.1 ReceptoPharm Company Information
 - 11.10.2 ReceptoPharm Adrenoleukodystrophy Treatment Product Offered
 - 11.10.3 ReceptoPharm Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.10.4 ReceptoPharm Main Business Overview
 - 11.10.5 ReceptoPharm Latest Developments
- 11.11 The Myelin Project
 - 11.11.1 The Myelin Project Company Information
 - 11.11.2 The Myelin Project Adrenoleukodystrophy Treatment Product Offered
 - 11.11.3 The Myelin Project Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.11.4 The Myelin Project Main Business Overview
 - 11.11.5 The Myelin Project Latest Developments
- 11.12 SOM Biotech
 - 11.12.1 SOM Biotech Company Information
 - 11.12.2 SOM Biotech Adrenoleukodystrophy Treatment Product Offered
 - 11.12.3 SOM Biotech Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.12.4 SOM Biotech Main Business Overview

- 11.12.5 SOM Biotech Latest Developments
- 11.13 Viking Therapeutics
 - 11.13.1 Viking Therapeutics Company Information
 - 11.13.2 Viking Therapeutics Adrenoleukodystrophy Treatment Product Offered
 - 11.13.3 Viking Therapeutics Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.13.4 Viking Therapeutics Main Business Overview
 - 11.13.5 Viking Therapeutics Latest Developments
- 11.14 Nutra Pharma Corporation
 - 11.14.1 Nutra Pharma Corporation Company Information
 - 11.14.2 Nutra Pharma Corporation Adrenoleukodystrophy Treatment Product Offered
 - 11.14.3 Nutra Pharma Corporation Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.14.4 Nutra Pharma Corporation Main Business Overview
 - 11.14.5 Nutra Pharma Corporation Latest Developments
- 11.15 Genetix Biotech
 - 11.15.1 Genetix Biotech Company Information
 - 11.15.2 Genetix Biotech Adrenoleukodystrophy Treatment Product Offered
 - 11.15.3 Genetix Biotech Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.15.4 Genetix Biotech Main Business Overview
 - 11.15.5 Genetix Biotech Latest Developments
- 11.16 Magenta Therapeutics
 - 11.16.1 Magenta Therapeutics Company Information
 - 11.16.2 Magenta Therapeutics Adrenoleukodystrophy Treatment Product Offered
 - 11.16.3 Magenta Therapeutics Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.16.4 Magenta Therapeutics Main Business Overview
 - 11.16.5 Magenta Therapeutics Latest Developments
- 11.17 NeuroVia
 - 11.17.1 NeuroVia Company Information
 - 11.17.2 NeuroVia Adrenoleukodystrophy Treatment Product Offered
 - 11.17.3 NeuroVia Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.17.4 NeuroVia Main Business Overview
 - 11.17.5 NeuroVia Latest Developments
- 11.18 Novartis
 - 11.18.1 Novartis Company Information
 - 11.18.2 Novartis Adrenoleukodystrophy Treatment Product Offered

11.18.3 Novartis Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.18.4 Novartis Main Business Overview

11.18.5 Novartis Latest Developments

11.19 CELGENE CORPORATION

11.19.1 CELGENE CORPORATION Company Information

11.19.2 CELGENE CORPORATION Adrenoleukodystrophy Treatment Product Offered

11.19.3 CELGENE CORPORATION Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.19.4 CELGENE CORPORATION Main Business Overview

11.19.5 CELGENE CORPORATION Latest Developments

11.20 Jazz Pharmaceuticals

11.20.1 Jazz Pharmaceuticals Company Information

11.20.2 Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Product Offered

11.20.3 Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.20.4 Jazz Pharmaceuticals Main Business Overview

11.20.5 Jazz Pharmaceuticals Latest Developments

11.21 Sanofi

11.21.1 Sanofi Company Information

11.21.2 Sanofi Adrenoleukodystrophy Treatment Product Offered

11.21.3 Sanofi Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.21.4 Sanofi Main Business Overview

11.21.5 Sanofi Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Adrenoleukodystrophy Treatment Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)

Table 2. Major Players of Oral Drugs

Table 3. Major Players of Parenteral Drugs

Table 4. Adrenoleukodystrophy Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)

Table 5. Global Adrenoleukodystrophy Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 6. Global Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Table 7. Adrenoleukodystrophy Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)

Table 8. Global Adrenoleukodystrophy Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 9. Global Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Table 10. Global Adrenoleukodystrophy Treatment Revenue by Players (2018-2023) & (\$ Millions)

Table 11. Global Adrenoleukodystrophy Treatment Revenue Market Share by Player (2018-2023)

Table 12. Adrenoleukodystrophy Treatment Key Players Head office and Products Offered

Table 13. Adrenoleukodystrophy Treatment Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

Table 14. New Products and Potential Entrants

Table 15. Mergers & Acquisitions, Expansion

Table 16. Global Adrenoleukodystrophy Treatment Market Size by Regions 2018-2023 & (\$ Millions)

Table 17. Global Adrenoleukodystrophy Treatment Market Size Market Share by Regions (2018-2023)

Table 18. Global Adrenoleukodystrophy Treatment Revenue by Country/Region (2018-2023) & (\$ millions)

Table 19. Global Adrenoleukodystrophy Treatment Revenue Market Share by Country/Region (2018-2023)

Table 20. Americas Adrenoleukodystrophy Treatment Market Size by Country

(2018-2023) & (\$ Millions)

Table 21. Americas Adrenoleukodystrophy Treatment Market Size Market Share by Country (2018-2023)

Table 22. Americas Adrenoleukodystrophy Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 23. Americas Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Table 24. Americas Adrenoleukodystrophy Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 25. Americas Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Table 26. APAC Adrenoleukodystrophy Treatment Market Size by Region (2018-2023) & (\$ Millions)

Table 27. APAC Adrenoleukodystrophy Treatment Market Size Market Share by Region (2018-2023)

Table 28. APAC Adrenoleukodystrophy Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 29. APAC Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Table 30. APAC Adrenoleukodystrophy Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 31. APAC Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Table 32. Europe Adrenoleukodystrophy Treatment Market Size by Country (2018-2023) & (\$ Millions)

Table 33. Europe Adrenoleukodystrophy Treatment Market Size Market Share by Country (2018-2023)

Table 34. Europe Adrenoleukodystrophy Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 35. Europe Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Table 36. Europe Adrenoleukodystrophy Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 37. Europe Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Table 38. Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Region (2018-2023) & (\$ Millions)

Table 39. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Market Share by Region (2018-2023)

Table 40. Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 41. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Table 42. Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 43. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Table 44. Key Market Drivers & Growth Opportunities of Adrenoleukodystrophy Treatment

Table 45. Key Market Challenges & Risks of Adrenoleukodystrophy Treatment

Table 46. Key Industry Trends of Adrenoleukodystrophy Treatment

Table 47. Global Adrenoleukodystrophy Treatment Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 48. Global Adrenoleukodystrophy Treatment Market Size Market Share Forecast by Regions (2024-2029)

Table 49. Global Adrenoleukodystrophy Treatment Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 50. Global Adrenoleukodystrophy Treatment Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 51. bluebird bio Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 52. bluebird bio Adrenoleukodystrophy Treatment Product Offered

Table 53. bluebird bio Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 54. bluebird bio Main Business

Table 55. bluebird bio Latest Developments

Table 56. Orpheris Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 57. Orpheris Adrenoleukodystrophy Treatment Product Offered

Table 58. Orpheris Main Business

Table 59. Orpheris Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 60. Orpheris Latest Developments

Table 61. MedDay Pharmaceuticals Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 62. MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Product Offered

Table 63. MedDay Pharmaceuticals Main Business

Table 64. MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Revenue (\$

million), Gross Margin and Market Share (2018-2023)

Table 65. MedDay Pharmaceuticals Latest Developments

Table 66. MINORYX THERAPEUTICS SL Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 67. MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Product Offered

Table 68. MINORYX THERAPEUTICS SL Main Business

Table 69. MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 70. MINORYX THERAPEUTICS SL Latest Developments

Table 71. Pfizer Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 72. Pfizer Adrenoleukodystrophy Treatment Product Offered

Table 73. Pfizer Main Business

Table 74. Pfizer Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 75. Pfizer Latest Developments

Table 76. Amgen Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 77. Amgen Adrenoleukodystrophy Treatment Product Offered

Table 78. Amgen Main Business

Table 79. Amgen Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 80. Amgen Latest Developments

Table 81. AstraZeneca Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 82. AstraZeneca Adrenoleukodystrophy Treatment Product Offered

Table 83. AstraZeneca Main Business

Table 84. AstraZeneca Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 85. AstraZeneca Latest Developments

Table 86. Abbott Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 87. Abbott Adrenoleukodystrophy Treatment Product Offered

Table 88. Abbott Main Business

Table 89. Abbott Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 90. Abbott Latest Developments

Table 91. agtc Details, Company Type, Adrenoleukodystrophy Treatment Area Served

and Its Competitors

Table 92. agtc Adrenoleukodystrophy Treatment Product Offered

Table 93. agtc Main Business

Table 94. agtc Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 95. agtc Latest Developments

Table 96. ReceptoPharm Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 97. ReceptoPharm Adrenoleukodystrophy Treatment Product Offered

Table 98. ReceptoPharm Main Business

Table 99. ReceptoPharm Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 100. ReceptoPharm Latest Developments

Table 101. The Myelin Project Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 102. The Myelin Project Adrenoleukodystrophy Treatment Product Offered

Table 103. The Myelin Project Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 104. The Myelin Project Main Business

Table 105. The Myelin Project Latest Developments

Table 106. SOM Biotech Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 107. SOM Biotech Adrenoleukodystrophy Treatment Product Offered

Table 108. SOM Biotech Main Business

Table 109. SOM Biotech Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 110. SOM Biotech Latest Developments

Table 111. Viking Therapeutics Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 112. Viking Therapeutics Adrenoleukodystrophy Treatment Product Offered

Table 113. Viking Therapeutics Main Business

Table 114. Viking Therapeutics Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 115. Viking Therapeutics Latest Developments

Table 116. Nutra Pharma Corporation Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 117. Nutra Pharma Corporation Adrenoleukodystrophy Treatment Product Offered

Table 118. Nutra Pharma Corporation Main Business

Table 119. Nutra Pharma Corporation Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 120. Nutra Pharma Corporation Latest Developments

Table 121. Genetix Biotech Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 122. Genetix Biotech Adrenoleukodystrophy Treatment Product Offered

Table 123. Genetix Biotech Main Business

Table 124. Genetix Biotech Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 125. Genetix Biotech Latest Developments

Table 126. Magenta Therapeutics Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 127. Magenta Therapeutics Adrenoleukodystrophy Treatment Product Offered

Table 128. Magenta Therapeutics Main Business

Table 129. Magenta Therapeutics Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 130. Magenta Therapeutics Latest Developments

Table 131. NeuroVia Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 132. NeuroVia Adrenoleukodystrophy Treatment Product Offered

Table 133. NeuroVia Main Business

Table 134. NeuroVia Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 135. NeuroVia Latest Developments

Table 136. Novartis Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 137. Novartis Adrenoleukodystrophy Treatment Product Offered

Table 138. Novartis Main Business

Table 139. Novartis Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 140. Novartis Latest Developments

Table 141. CELGENE CORPORATION Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 142. CELGENE CORPORATION Adrenoleukodystrophy Treatment Product Offered

Table 143. CELGENE CORPORATION Main Business

Table 144. CELGENE CORPORATION Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 145. CELGENE CORPORATION Latest Developments

Table 146. Jazz Pharmaceuticals Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 147. Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Product Offered

Table 148. Jazz Pharmaceuticals Main Business

Table 149. Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 150. Jazz Pharmaceuticals Latest Developments

Table 151. Sanofi Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors

Table 152. Sanofi Adrenoleukodystrophy Treatment Product Offered

Table 153. Sanofi Adrenoleukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 154. Sanofi Main Business

Table 155. Sanofi Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Adrenoleukodystrophy Treatment Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Adrenoleukodystrophy Treatment Market Size Growth Rate 2018-2029 (\$ Millions)

Figure 6. Adrenoleukodystrophy Treatment Sales by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Figure 7. Adrenoleukodystrophy Treatment Sales Market Share by Country/Region (2022)

Figure 8. Adrenoleukodystrophy Treatment Sales Market Share by Country/Region (2018, 2022 & 2029)

Figure 9. Global Adrenoleukodystrophy Treatment Market Size Market Share by Type in 2022

Figure 10. Adrenoleukodystrophy Treatment in Hospital

Figure 11. Global Adrenoleukodystrophy Treatment Market: Hospital (2018-2023) & (\$ Millions)

Figure 12. Adrenoleukodystrophy Treatment in Clinic

Figure 13. Global Adrenoleukodystrophy Treatment Market: Clinic (2018-2023) & (\$ Millions)

Figure 14. Adrenoleukodystrophy Treatment in Home Care

Figure 15. Global Adrenoleukodystrophy Treatment Market: Home Care (2018-2023) & (\$ Millions)

Figure 16. Global Adrenoleukodystrophy Treatment Market Size Market Share by Application in 2022

Figure 17. Global Adrenoleukodystrophy Treatment Revenue Market Share by Player in 2022

Figure 18. Global Adrenoleukodystrophy Treatment Market Size Market Share by Regions (2018-2023)

Figure 19. Americas Adrenoleukodystrophy Treatment Market Size 2018-2023 (\$ Millions)

Figure 20. APAC Adrenoleukodystrophy Treatment Market Size 2018-2023 (\$ Millions)

Figure 21. Europe Adrenoleukodystrophy Treatment Market Size 2018-2023 (\$ Millions)

Figure 22. Middle East & Africa Adrenoleukodystrophy Treatment Market Size 2018-2023 (\$ Millions)

Figure 23. Americas Adrenoleukodystrophy Treatment Value Market Share by Country in 2022

Figure 24. United States Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 25. Canada Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 26. Mexico Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 27. Brazil Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 28. APAC Adrenoleukodystrophy Treatment Market Size Market Share by Region in 2022

Figure 29. APAC Adrenoleukodystrophy Treatment Market Size Market Share by Type in 2022

Figure 30. APAC Adrenoleukodystrophy Treatment Market Size Market Share by Application in 2022

Figure 31. China Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 32. Japan Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 33. Korea Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 34. Southeast Asia Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 35. India Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 36. Australia Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 37. Europe Adrenoleukodystrophy Treatment Market Size Market Share by Country in 2022

Figure 38. Europe Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Figure 39. Europe Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Figure 40. Germany Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 41. France Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 42. UK Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$

Millions)

Figure 43. Italy Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 44. Russia Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 45. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Market Share by Region (2018-2023)

Figure 46. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Figure 47. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Figure 48. Egypt Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 49. South Africa Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 50. Israel Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 51. Turkey Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 52. GCC Country Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 53. Americas Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 54. APAC Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 55. Europe Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 56. Middle East & Africa Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 57. United States Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 58. Canada Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 59. Mexico Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 60. Brazil Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 61. China Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 62. Japan Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 63. Korea Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 64. Southeast Asia Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 65. India Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 66. Australia Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 67. Germany Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 68. France Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 69. UK Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 70. Italy Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 71. Russia Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 72. Spain Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 73. Egypt Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 74. South Africa Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 75. Israel Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 76. Turkey Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 77. GCC Countries Adrenoleukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 78. Global Adrenoleukodystrophy Treatment Market Size Market Share Forecast by Type (2024-2029)

Figure 79. Global Adrenoleukodystrophy Treatment Market Size Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Adrenoleukodystrophy Treatment Market Growth (Status and Outlook) 2023-2029

Product link: <https://marketpublishers.com/r/G58896F17D8BEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G58896F17D8BEN.html>